Table 1.

Summary of Efficacy Measures in 2 Pivotal, Phase III Clinical Trials

Efficacy measure	Goodman, et al. (2009) [6]	Goodman, et al. (2010) [7]
T25FW responders
(vs placebo)	35 % (8 %)	42.9 % (9.3 %)
Average change in walking speed in responders (vs placebo)	25.2 % (4.7 %)	24.7 % (7.7 %)
Average change in MSWS-12 score (vs placebo)	-6.84 (0.05)	-6.04 (0.85)
Average change in LEMMT score (vs placebo)	0.18 (0.04)	0.145 (0.042)

LEMMT = Lower Extremity Manual Muscle Test [6, 7]; MSWS-12 = 12-Item Multiple Sclerosis Walking Scale; T25FW test = timed 25-foot walk test

All differences shown were significant with p value < 0.05